85 related articles for article (PubMed ID: 21385146)
1. Response to: Demarteau N, Standaert B. Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer. J Med Econ 2010;13:324-38.
Hillemanns P
J Med Econ; 2011; 14(2):262-6. PubMed ID: 21385146
[No Abstract] [Full Text] [Related]
2. Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer.
Demarteau N; Standaert B
J Med Econ; 2010; 13(2):324-38. PubMed ID: 20504110
[TBL] [Abstract][Full Text] [Related]
3. A brief history of economic evaluation for human papillomavirus vaccination policy.
Beutels P; Jit M
Sex Health; 2010 Sep; 7(3):352-8. PubMed ID: 20719227
[TBL] [Abstract][Full Text] [Related]
4. Evaluating societal preferences for human papillomavirus vaccine and cervical smear test screening programme.
Oteng B; Marra F; Lynd LD; Ogilvie G; Patrick D; Marra CA
Sex Transm Infect; 2011 Feb; 87(1):52-7. PubMed ID: 20956352
[TBL] [Abstract][Full Text] [Related]
5. [Shortsighted economics behind the choice of HPV vaccine. Sweden misses the chance the chance "to eradicate" condyloma].
Rylander E
Lakartidningen; 2010 Jun 30-Jul 20; 107(26-28):1688-9. PubMed ID: 20701147
[No Abstract] [Full Text] [Related]
6. Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise.
Torvinen S; Nieminen P; Lehtinen M; Paavonen J; Demarteau N; Hahl J
J Med Econ; 2010; 13(2):284-94. PubMed ID: 20482244
[TBL] [Abstract][Full Text] [Related]
7. (Not) warts and all.
Hammond P
BMJ; 2008 Oct; 337():a2186. PubMed ID: 18948345
[No Abstract] [Full Text] [Related]
8. HPV vaccine strategies: the cost of HPV and the choice of vaccine.
Morris SR
Sex Transm Infect; 2009 Sep; 85(5):315-6. PubMed ID: 19773455
[No Abstract] [Full Text] [Related]
9. Cost–effectiveness of catch-up programs in human papillomavirus vaccination.
de Peuter MA; Littlewood KJ; Annemans L; Largeron N; Quilici S
Expert Rev Vaccines; 2010 Oct; 9(10):1187-201. PubMed ID: 20923269
[TBL] [Abstract][Full Text] [Related]
10. Population effectiveness, not efficacy, should decide who gets vaccinated against human papillomavirus via publicly funded programs.
Castle PE; Zhao FH
J Infect Dis; 2011 Aug; 204(3):335-7. PubMed ID: 21742829
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
de Kok IM; van Ballegooijen M; Habbema JD
J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
[TBL] [Abstract][Full Text] [Related]
12. The economic impact of HPV vaccines: not just cervical cancer.
Myers ER
Am J Obstet Gynecol; 2008 May; 198(5):487-8. PubMed ID: 18455522
[No Abstract] [Full Text] [Related]
13. Impact of vaccinating boys and men against HPV in the United States.
Elbasha EH; Dasbach EJ
Vaccine; 2010 Oct; 28(42):6858-67. PubMed ID: 20713101
[TBL] [Abstract][Full Text] [Related]
14. The new human papillomavirus (HPV) vaccine: pros and cons for pediatric and adolescent health.
Thomas TL
Pediatr Nurs; 2008; 34(5):429-31. PubMed ID: 19051848
[TBL] [Abstract][Full Text] [Related]
15. Debate begins over public funding for HPV vaccine.
Comeau P
CMAJ; 2007 Mar; 176(7):913-4. PubMed ID: 17374749
[No Abstract] [Full Text] [Related]
16. Genital warts: mountains or molehills?
Hull SC; Caplan AL
Lancet Infect Dis; 2008 May; 8(5):277-8. PubMed ID: 18471771
[No Abstract] [Full Text] [Related]
17. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.
Sinanovic E; Moodley J; Barone MA; Mall S; Cleary S; Harries J
Vaccine; 2009 Oct; 27(44):6196-202. PubMed ID: 19698807
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic vaccines for human papillomavirus: a bright future for cervical cancer prevention.
Szarewski A
J Med Screen; 2005; 12(4):163-5. PubMed ID: 16417690
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands.
Rogoza RM; Westra TA; Ferko N; Tamminga JJ; Drummond MF; Daemen T; Wilschut JC; Postma MJ
Vaccine; 2009 Jul; 27(35):4776-83. PubMed ID: 19539578
[TBL] [Abstract][Full Text] [Related]
20. Quadrivalent HPV vaccine. Wider cost benefits of vaccine.
O'Mahony C; Greenhouse P; Robinson A; Sonnex C
BMJ; 2010 Aug; 341():c4455. PubMed ID: 20724414
[No Abstract] [Full Text] [Related]
[Next] [New Search]
